Showing results (2041-2050 of 8,257) with videos related to
Sort By:
Pageof 826
Haematologica|June 30, 2022
Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modelingSarah Lawless, Simona Iacobelli, Nina Simone Knelange, et al.Haematologica|June 30, 2022
Clinical features of hepatitis E infections in patients with hematologic disordersSusanne Ghandili, Cecilia Lindhauer, Sven Pischke, et al.Haematologica|October 15, 2020
Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II studyAnders Lindholm Sørensen, Stine Ulrik Mikkelsen, Trine Alma Knudsen, et al.Haematologica|October 15, 2020
A mutated factor X activatable by thrombin corrects bleedings in vivo in a rabbit model of antibody-induced hemophilia AToufik Abache, Alexandre Fontayne, Dominique Grenier, et al.Haematologica|October 15, 2020
Repurposing pyridoxamine for therapeutic intervention of intravascular cell-cell interactions in mouse models of sickle cell diseaseJing Li, Si-Yeon Jeong, Bei Xiong, et al.Haematologica|October 15, 2020
The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programsDebora Soncini, Stefania Orecchioni, Samantha Ruberti, et al.Haematologica|October 15, 2020
Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohortJohanne M Holst, Trine L Plesner, Martin B Pedersen, et al.Haematologica|October 15, 2020
Murine tissue factor disulfide mutation causes a bleeding phenotype with sex specific organ pathology and lethalitySusanna H M Sluka, Simon F Stämpfli, Alexander Akhmedov, et al.Haematologica|October 15, 2020
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?Ehab Atallah, Charles A SchifferHaematologica|October 15, 2020
Pediatric acute lymphoblastic leukemiaHiroto Inaba, Charles G MullighanPageof 826